Association between diagnosis to treatment interval and survival outcomes in diffuse large B-cell lymphoma using a causal inference approach

Timely care is an important aspect of health care quality, particularly for aggressive malignancies like diffuse large B-cell lymphoma (DLBCL). However, the prognostic impact of diagnosis-to-treatment interval (DTI) in DLBCL remains inconclusive. Thus, we evaluated the impact of DTI on survival outcomes using causal inference methods. A total of 2610 DLBCL patients treated with immunochemotherapy from the Lymphoma and Related Diseases Registry were included. Inverse probability of treatment weighting (IPTW) based on propensity scores estimated via generalized boosted models was applied to adjust for differences in adverse prognostic factors between DTI cohorts. The median DTI was 15 days, with an interquartile range of 8–28 days. Patients who received treatment within 14 days had adverse clinical characteristics, including stage III/IV, poor performance status, elevated LDH, B-symptoms, bulk disease, > 1 extranodal sites involved and anaemia. In univariable analyses, shorter DTI (≤ 14 days) was associated with worse overall survival (OS) and progression-free survival (PFS). However, after IPTW adjustment, shorter DTI was significantly associated with improved OS (adjusted hazard ratio = 0.68; 95% CI: 0.52, 0.88). our study suggest that short DTI should be interpreted primarily as a marker of disease severity rather than as an adverse prognostic factor itself.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-14
DOI
https://doi.org/10.1038/s41598-026-78239-1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between diagnosis to treatment interval and survival outcomes in diffuse large B-cell lymphoma using a causal inference approach

Eliza Anne Hawkes, Eliza Chung, Adugnaw Zeleke Alem, Nalini Kant Pati et al.
2 links
Scientific Reports
Lymphoma Diagnosis and Treatment
article

Association between diagnosis to treatment interval and survival outcomes in diffuse large B-cell lymphoma using a causal inference approach

Eliza Anne Hawkes, Eliza Chung, Adugnaw Zeleke Alem, Nalini Kant Pati, Itismita Mohanty, Cameron J. Wellard, Stephen Opat, Zoe McQuilten, Theophile Niyonsenga, Erica M. Wood
article en

Abstract

Timely care is an important aspect of health care quality, particularly for aggressive malignancies like diffuse large B-cell lymphoma (DLBCL). However, the prognostic impact of diagnosis-to-treatment interval (DTI) in DLBCL remains inconclusive. Thus, we evaluated the impact of DTI on survival outcomes using causal inference methods. A total of 2610 DLBCL patients treated with immunochemotherapy from the Lymphoma and Related Diseases Registry were included. Inverse probability of treatment weighting (IPTW) based on propensity scores estimated via generalized boosted models was applied to adjust for differences in adverse prognostic factors between DTI cohorts. The median DTI was 15 days, with an interquartile range of 8–28 days. Patients who received treatment within 14 days had adverse clinical characteristics, including stage III/IV, poor performance status, elevated LDH, B-symptoms, bulk disease, > 1 extranodal sites involved and anaemia. In univariable analyses, shorter DTI (≤ 14 days) was associated with worse overall survival (OS) and progression-free survival (PFS). However, after IPTW adjustment, shorter DTI was significantly associated with improved OS (adjusted hazard ratio = 0.68; 95% CI: 0.52, 0.88). our study suggest that short DTI should be interpreted primarily as a marker of disease severity rather than as an adverse prognostic factor itself.

Scientific Reports
Australian National University (AU), University of Canberra (AU), Canberra Hospital (AU), Alfred Health (AU), Austin Health (AU), Olivia Newton-John Cancer Research Institute (AU), Monash University (AU), University of Gondar (ET)
Australian Government, University of Canberra
Good health and well-being
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon